Literature DB >> 26630226

Frequency and Spectrum of MED12 Exon 2 Mutations in Multiple Versus Solitary Uterine Leiomyomas From Russian Patients.

Natalia S Osinovskaya1, Olga V Malysheva, Natalia Yu Shved, Tatyana E Ivashchenko, Iskender Yu Sultanov, Olga A Efimova, Maria I Yarmolinskaya, Vitaly F Bezhenar, Vladislav S Baranov.   

Abstract

Uterine leiomyomas (ULs) are common benign tumors affecting women of different ethnicities. A large proportion of UL has mutations in MED12. Multiple and solitary ULs usually manifest with different severities, suggesting that their origin and growth pattern may be driven by different molecular mechanisms. Here, we compared the frequency and the spectrum of MED12 exon 2 mutations between multiple (n=82) and solitary (n=40) ULs from Russian patients. Overall, we detected MED12 exon 2 mutations in 51.6% (63/122) of ULs. The frequency of MED12 exon 2 mutations was almost two-fold higher in samples from the multiple UL patients than in those from the solitary UL patients - 61% (50/82) versus 32.5% (13/40). The increased MED12 exon 2 mutation frequency in the multiple ULs was not accompanied by significant alterations in the spectrum of mutation categories, which included missense mutations, deletions, splicing defects, and multiple (double/triple) mutations. Each mutation category had a unique mutation set, comprising both frequent and rarely encountered mutations, which did and did not overlap between the studied groups, respectively. We conclude that in contrast to the solitary ULs, the multiple ULs predominantly originate through MED12-associated mechanisms. The nature of these mechanisms seems to be similar in solitary and multiple ULs, as they contain similar mutations. In multiple UL patients, they are likely to be nonsporadic, indicating the existence of specific factors predisposing to multiple UL development. These data suggest that to clearly understand UL pathogenesis, solitary and multiple tumors should probably be analyzed as separate sets.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26630226     DOI: 10.1097/PGP.0000000000000255

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  10 in total

1.  Development of Primary Monolayer Cell Model and Organotypic Model of Uterine Leiomyoma.

Authors:  Natalia Shved; Anna Egorova; Natalia Osinovskaya; Anton Kiselev
Journal:  Methods Protoc       Date:  2022-02-06

2.  Prevalence and clinical significance of mediator complex subunit 12 mutations in 362 Han Chinese samples with uterine leiomyoma.

Authors:  Juan Wu; Yang Zou; Yong Luo; Jiu-Bai Guo; Fa-Ying Liu; Jiang-Yan Zhou; Zi-Yu Zhang; Lei Wan; Ou-Ping Huang
Journal:  Oncol Lett       Date:  2017-05-04       Impact factor: 2.967

3.  Leiomyoma with bizarre nuclei: a morphological, immunohistochemical and molecular analysis of 31 cases.

Authors:  Jennifer A Bennett; Britta Weigelt; Sarah Chiang; Pier Selenica; Ying-Bei Chen; Ann Bialik; Rui Bi; Anne M Schultheis; Raymond S Lim; Charlotte K Y Ng; Vicente Morales-Oyarvide; Robert H Young; Victor E Reuter; Robert A Soslow; Esther Oliva
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

Review 4.  Pathogenomics of Uterine Fibroids Development.

Authors:  Vladislav S Baranov; Natalia S Osinovskaya; Maria I Yarmolinskaya
Journal:  Int J Mol Sci       Date:  2019-12-06       Impact factor: 5.923

5.  Familial Predisposition to Leiomyomata: Searching for Protective Genetic Factors.

Authors:  Maria V Kuznetsova; Nelly S Sogoyan; Andrew J Donnikov; Dmitry Y Trofimov; Leila V Adamyan; Natalia D Mishina; Jekaterina Shubina; Dmitry V Zelensky; Gennady T Sukhikh
Journal:  Biomedicines       Date:  2022-02-21

6.  Frequency of MED12 Mutation in Relation to Tumor and Patient's Clinical Characteristics: a Meta-analysis.

Authors:  Chao He; William Nelson; Hui Li; Ya-Dong Xu; Xue-Jiao Dai; Ying-Xiong Wang; Yu-Bin Ding; Yan-Ping Li; Tian Li
Journal:  Reprod Sci       Date:  2021-02-10       Impact factor: 3.060

7.  Analysis of MED12 Mutation in Multiple Uterine Leiomyomas in South Korean patients.

Authors:  Minkyoung Lee; Keunyoung Cheon; Boah Chae; Hyesung Hwang; Hyun-Kyung Kim; Youn-Jee Chung; Jae-Yen Song; Hyun-Hee Cho; Jang-Heub Kim; Mee-Ran Kim
Journal:  Int J Med Sci       Date:  2018-01-01       Impact factor: 3.738

8.  Multiple clinical characteristics separate MED12-mutation-positive and -negative uterine leiomyomas.

Authors:  Hanna-Riikka Heinonen; Annukka Pasanen; Oskari Heikinheimo; Tomas Tanskanen; Kimmo Palin; Jaana Tolvanen; Pia Vahteristo; Jari Sjöberg; Esa Pitkänen; Ralf Bützow; Netta Mäkinen; Lauri A Aaltonen
Journal:  Sci Rep       Date:  2017-04-21       Impact factor: 4.379

9.  Submucous Fibroids, Fertility, and Possible Correlation to Pseudocapsule Thickness in Reproductive Surgery.

Authors:  Andrea Tinelli; Ioannis Kosmas; Ospan A Mynbaev; Alessandro Favilli; Grigoris Gimbrizis; Radmila Sparic; Marcello Pellegrino; Antonio Malvasi
Journal:  Biomed Res Int       Date:  2018-09-03       Impact factor: 3.411

10.  Cytogenomic Profile of Uterine Leiomyoma: In Vivo vs. In Vitro Comparison.

Authors:  Alla S Koltsova; Olga A Efimova; Olga V Malysheva; Natalia S Osinovskaya; Thomas Liehr; Ahmed Al-Rikabi; Natalia Yu Shved; Iskender Yu Sultanov; Olga G Chiryaeva; Maria I Yarmolinskaya; Nikolai I Polenov; Vladislava V Kunitsa; Maka I Kakhiani; Tatyana G Tral; Gulrukhsor Kh Tolibova; Olesya N Bespalova; Igor Yu Kogan; Andrey S Glotov; Vladislav S Baranov; Anna A Pendina
Journal:  Biomedicines       Date:  2021-11-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.